Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Popular diabetes and weight-loss drugs, including Ozempic (NVO) and Zepbound (LLY), may have a potential link with several ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.

A beloved company that has been part of the fabric of the US and has served hundreds of millions of customers around the ...

Criminals are targeting pharmacies and stealing weight-loss medication in a country with body image insecurities and where ...

With patriotism supercharging consumer spending habits, many are asking if their investments should be local as well ...

Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as well as their implications for other applications like kidney disease and ...

Novo Nordisk's semaglutide, which could be the first oral alternative to injectable GLP-1 agonists in type 2 diabetes, has started phase III trials. If it reaches the market, the oral formulation ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...